PAYO vs. MEDP, WPP, HQY, QXO, BILI, LYFT, MARA, WSC, AMTM, and ETSY
Should you be buying Payoneer Global stock or one of its competitors? The main competitors of Payoneer Global include Medpace (MEDP), WPP (WPP), HealthEquity (HQY), QXO (QXO), Bilibili (BILI), Lyft (LYFT), MARA (MARA), WillScot Mobile Mini (WSC), Amentum (AMTM), and Etsy (ETSY). These companies are all part of the "business services" industry.
Payoneer Global vs.
Payoneer Global (NASDAQ:PAYO) and Medpace (NASDAQ:MEDP) are both mid-cap business services companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.
Medpace has a net margin of 19.17% compared to Payoneer Global's net margin of 13.82%. Medpace's return on equity of 51.48% beat Payoneer Global's return on equity.
Medpace received 294 more outperform votes than Payoneer Global when rated by MarketBeat users. However, 71.95% of users gave Payoneer Global an outperform vote while only 62.81% of users gave Medpace an outperform vote.
Medpace has higher revenue and earnings than Payoneer Global. Medpace is trading at a lower price-to-earnings ratio than Payoneer Global, indicating that it is currently the more affordable of the two stocks.
In the previous week, Medpace had 13 more articles in the media than Payoneer Global. MarketBeat recorded 22 mentions for Medpace and 9 mentions for Payoneer Global. Medpace's average media sentiment score of 1.41 beat Payoneer Global's score of 1.14 indicating that Medpace is being referred to more favorably in the news media.
Payoneer Global presently has a consensus price target of $10.71, suggesting a potential upside of 55.96%. Medpace has a consensus price target of $349.30, suggesting a potential upside of 19.20%. Given Payoneer Global's stronger consensus rating and higher probable upside, equities analysts clearly believe Payoneer Global is more favorable than Medpace.
82.2% of Payoneer Global shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 5.6% of Payoneer Global shares are held by insiders. Comparatively, 20.3% of Medpace shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Payoneer Global has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.
Summary
Medpace beats Payoneer Global on 13 of the 19 factors compared between the two stocks.
Get Payoneer Global News Delivered to You Automatically
Sign up to receive the latest news and ratings for PAYO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Payoneer Global Competitors List
Related Companies and Tools
This page (NASDAQ:PAYO) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy PAYO Stock Free PAYO Stock Alerts